106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2020 All rights reserved
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
melanoma-guidelines. Copyright © 2020 by American Society of Clinical Oncolog y.
All rights reserved.
ASCOMEL03203
Abbreviations
CLND, completion lymph node dissection; PD1, programmed death 1; SLNB, sentinel lymph
node biopsy; US FDA, United States Food and Drug Administration
Source
Rahul Seth, Hans Messersmith, Varinder Kaur, John M. Kirkwood, Ragini Kudchadkar, Jennifer
Leigh McQuade, Anthony Provenzano, Umang Swami, Jeffrey Weber, Krishna C. Alluri, Sanjiv
Agarwala, Paolo A. Ascierto, Michael B. Atkins, Nancy Davis, Marc S. Ernstoff, Mark B. Faries,
Jason S. Gold, Samantha Guild, David E. Gyorki, Nikhil I. Khushalani, Michael O. Meyers,
Caroline Robert, Mario Santinami, Amikar Sehdev, Vernon K. Sondak, Gilliosa Spurrier, Katy
K. Tsai, Alexander van Akkooi, Pauline Funchain. Systemic erapy for Melanoma: ASCO
Guideline. J Clin Oncol. 2020 March 31doi: 10.1200/JCO.20.00198
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical tools
and resources, is available at www.asco.org/melanoma-guidelines.
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-based B Benefits
outweigh harms
H High Strong
FC
Formal consensus H Harms
outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
N No
recommendation
U Unknown Ins Insufficient